Uro-oncology · Internal Medicine

Internal Medicine · Clinical Specialties

How it begins

Compendio exhaustivo de los tumores malignos del tracto urológico: cáncer de próstata, vejiga, riñón, testículo y tumores adrenales — biología molecular, clasificación histológica, estadificación, tratamiento sistémico, inmunoterapia y algoritmos diagnóstico-terapéuticos actualizados.

What it covers

1. Overview of Urooncology
2. Global Epidemiology of Uro-oncological Tumors
3. Prostate Cancer: Epidemiology and Risk Factors
4. · Risk Factors
5. Biology and Pathology of Prostate Cancer
6. · Histogenesis and Histological Types
7. · Prostatic Intraepithelial Neoplasia (PIN)
8. · Grading System: Gleason and ISUP Classification 2014
9. · Molecular Alterations
10. Prostate Cancer Diagnosis: PSA and Biopsy
11. · PSA: Biology and Limitations
12. · PSA Derivatives to Improve Specificity
13. · New Generation Biomarkers
14. · Multiparametric Magnetic Resonance (mpMRI) and PI-RADS System
15. · Prostate Biopsy Techniques
16. PCa Staging and Risk Groups
17. · TNM System (AJCC 8th Ed. / UAE 2024)
18. · UAE 2024 Risk Groups (Localized CaP/Locally Advanced)
19. · Staging of Metastatic Disease: PSMA-PET and Subclassification
20. Treatment of Localized and Locally Advanced Prostate Cancer
21. · Active Surveillance (VA)
22. · Radical Prostatectomy (RP)
23. · Intensity Modulated Radiotherapy (IMRT) and Brachytherapy
24. · Androgen Deprivation (ADT) in Localized/Locally Advanced PCa
25. Castration Resistant Prostate Cancer (CRPC)
26. · Definition and Mechanisms of Resistance
27. · Therapeutic Sequence in CPHSm (High Intensity)
28. · Treatment of Post-Hormonal mCRPC
29. Bladder Cancer: Epidemiology and Risk Factors
30. Pathology of Bladder Cancer
31. · Histological Types
32. · Carcinoma In Situ (CIS) of the Bladder
33. · Molecular Classification of Muscle-Invasive CV
34. Non-Muscle-Invasive Bladder Cancer (NMIBC)
35. · Transurethral Resection of Bladder Tumor (TURBT)
36. · Risk Stratification and Intravesical Treatment
37. · Surveillance: Monitoring Protocol
38. Muscle-Invasive Bladder Cancer (MIBC)
39. · Neoadjuvant Chemotherapy (NCT)
40. · Radical Cystectomy (RC)
41. · Adjuvant Immunotherapy: Nivolumab
42. · Trimodal Bladder Preservation
43. Metastatic Bladder Cancer
44. Renal Cell Carcinoma: Epidemiology and Genetics
45. · Genetics of Clear Cell CRC: The VHL-HIF Pathway
46. · Hereditary CRC Syndromes
47. Histological Subtypes of CRC
48. Diagnosis and Imaging of CRC
49. · Clinical Presentation
50. · Multiphasic Renal CT
51. · Bosniak Classification System for Cystic Masses
52. Staging and Prognosis of CRC
53. · TNM and Localized CRC Surgery
54. · Prognostic Scores in Metastatic CRC: IMDC and MSKCC
55. Systemic Treatment of Advanced/Metastatic CRC
56. · First Line in Metastatic ccCRC (EAU/ESMO Recommendations 2024)
57. · Second Line and Subsequent Lines
58. · Management of Non-Clear Cell CRC
59. Testicular Germ Cell Tumors
60. · Histological Classification
61. · Genetic Alteration: Isochromosome 12p
62. · Risk Factors
63. Tumor Markers in TCG
64. IGCCCG Staging and Prognostic Groups
65. GCT Treatment: Orchiectomy, CT and Post-CT Surgery
66. · Radical Inguinal Orchiectomy
67. · TCG Stage I: Surveillance vs. Adjuvant Treatment
68. · Chemotherapy with BEP
69. · Post-Chemotherapy Residual Mass Surgery
70. · Rescue Chemotherapy
71. Urothelial Carcinoma of the Upper Urinary Tract (UTUC)
72. Adrenal Tumors of Oncological Relevance
73. · Adrenocortical carcinoma (ACC)
74. · Malignant Pheochromocytoma and Paraganglioma
75. Carcinoma of the Penis
76. Immuno-oncology in Uro-oncology
77. · Immune Control Points (ICIs) in Ur-oncology
78. · Predictive Biomarkers of Response to ICIs
79. · Immune-related Adverse Events (irAEs)
80. Directed Molecular Therapies in Uro-oncology
81. PARP Inhibitors and Homologous Recombination Deficiency (HRR)
82. · Mechanism of Action
83. · PARPi Approved in Ur-Oncology
84. · Importance of the Genomic Test in Uro-oncology
85. Diagnostic-Therapeutic Algorithms in Ur-Oncology
86. · Algorithm: Incidental Renal Mass
87. · Algorithm: Macroscopic Hematuria in Adults
88. · Algorithm: Testicular Mass